

WVA
WASHINGTON VACCINE ASSOCIATION

FY26 Annual Report

Dear Friends and Colleagues,

This year has reinforced how essential strong partnerships are to sustaining the Childhood Vaccine Program. Our work with the Washington State Department of Health (DOH) and the Washington Chapter of the American Academy of Pediatrics (WCAAP) has deepened in meaningful ways; bringing payer, provider, and public health perspectives together around a common goal: protecting access to childhood vaccines while strengthening the program's long-term stability.

Through these partnerships we are improving communication, supporting providers, encouraging responsible vaccine inventory practices, and building shared ownership of Washington's universal purchase model. With much about the future vaccine landscape still unknown, the challenges ahead are real, but so is our confidence in what we can accomplish together.

We extend our sincere thanks to our partners and board members; your expertise, leadership, and shared commitment make this work possible. We are grateful for the role each of you play in sustaining Washington's universal Childhood Vaccine Program for the children and families who rely on it.

John Dunn, MD, MPH
Board Chairman

RSV » Partnership in Action

In the Fall of 2025, Washington's Childhood Vaccine Program (CVP) faced overwhelming challenges compromising the WVA's ability to fund new vaccine orders. These included using financial reserves before insurers were authorized to be billed, excess RSV doses in provider clinics from the prior season, and rising waste and expiration of respiratory products. Due to these challenges, providers were unable to receive their requested orders of respiratory vaccines as the WVA needed to collect additional assessments to continue the flow of money into the CVP.

In response, the WVA worked quickly with public health partners to stabilize the system. Together, we made meaningful progress in expanding access to RSV protection across Washington. We coordinated our messaging, expanded training around vaccine inventory management, and facilitated product transfers to draw down excess inventory and place doses where they would be used.

The experience underscored an important lesson: long-term sustainability depends on early visibility, shared accountability, and strong operational habits across the vaccine program. By assisting with a coordinated response, the WVA and its partners staved off the short-term financial crisis and strengthened foundational awareness of our program and its vulnerabilities. Today, the WVA continues to work towards a sustainable future through strong partnership, robust communications, and on-going provider training.

During the 2025–26 respiratory season, RSV administration **increased by 11%** compared with the 2024–25 season.





Legislative Success

In 2025, the Washington Vaccine Association lobbied to support the state's efforts to address uncertainty in national vaccine policy and the committee tasked with setting pediatric immunization recommendations. House Bill 2242 was created to clarify the state's authority to issue its own immunization recommendations rather than relying upon federal guidelines and ensure health plans continue to cover those vaccine costs. After coalition building among immunization advocates, and robust debate in the legislature, it passed in March 2026, ensuring the future autonomy of the state to make important public health decisions.

Making Every Dose Count

Thanks to strong partners, **35,557 doses—valued at $5.88 million—** were successfully transferred to providers who needed them most, ensuring available vaccine was directed where it could best support patient access, sustain provider operations, and reduce waste.




FY26 VACCINES	DOSES	COST
Non-Respiratory Vaccines	18,975	$1.74M
COVID Vaccines	3,082	$239,363
Influenza Vaccines	4,242	$69,055
RSV Products	9,258	$3.84M
TOTAL	**35,557**	**$5.88M**

FY26 Financials

July 1, 2025 - June 30, 2026


Childhood Vaccine Funding Sources

Estimated Total: $213,538,416



WVA Program Expenditures

Total: $118,869,209



This chart reflects funding for WVA-funded vaccines on a cash basis. The audited financials are available at www.wavaccine.org.

WVA BOARD OF DIRECTORS

John B. Dunn, MD, MPH, Chair
Department of Pediatrics, Kaiser Permanente

Beth Harvey, MD, Vice Chair
South Sound Pediatrics

Edgar Marcuse, MD, MPH, FPIDS, Secretary
Professor Emeritus, Pediatrics, University of Washington

Steven Caplow, JD, Treasurer
Partner, Davis Wright Tremaine LLP

Helen Chea, MD
Pediatric Medical Director, Molina Healthcare

Kara Manley
Senior Network Contract Manager, Pacific Northwest, United Healthcare

Chad Murphy, PharmD
SVP, Clinical & Provider Operations and Pharmacy, Premera Blue Cross

Michele Roberts, MPH, MCHES
Assistant Secretary, Prevention and Community Health Division, Washington State Department of Health

Nicole Saint Clair, MD, FACOG
Executive Medical Director, Regence BlueShield WA

Hema Sivasubramanian, MD
Medical Director-Commercial, Aetna

WVA STAFF

Julia Walter Zell, MA, Esq.
Executive Director

Kerrie Walker, MA
Deputy Director

Cheri Cagle
Provider Support Specialist

Hailey Hoefer
Operations Support Specialist

HELMS & COMPANY, INC. STAFF

Patrick B. Miller, MPH
Administrative Director

Terri Perkins
Senior Client Support Specialist

P 888.928.2224 | **F** 888.928.2242
info@wavaccine.org | wavaccine.org

